# Gut Microbiota–Bile Acid Axis in Type 2 Diabetes–Associated Gallbladder Diseases: Mechanisms and Therapeutic Potential

## TL;DR

The gut microbiota and bile acids play a key role in gallbladder diseases linked to type 2 diabetes, offering new therapeutic possibilities.

## Contribution

This paper proposes the gut microbiota–bile acid axis as a novel integrative mechanism linking metabolic dysregulation and gallbladder disease progression in T2DM.

## Key findings

- Shifts in gut microbiota and bile acid metabolism contribute to lithogenic bile formation and gallbladder dysfunction in T2DM.
- Microbial translocation and LPS-driven inflammation reinforce a cycle linking gallstones, inflammation, and cancer.
- Microbiome- and bile acid-targeted therapies may improve biliary outcomes but require careful consideration of confounding factors.

## Abstract

Gallbladder diseases spanning cholelithiasis, cholecystitis, and gallbladder cancer represent a clinically heterogeneous continuum in which type 2 diabetes mellitus (T2DM) acts as a key metabolic modifier. Conventional models centered on bile supersaturation alone do not sufficiently account for the persistent inflammation and inter-individual variability frequently observed in practice. Here, we synthesize emerging evidence implicating the gut microbiota–bile acid (BA) axis as an integrative mechanism linking metabolic dysregulation, barrier dysfunction, and biliary pathobiology in the diabetic host. Hyperglycemia and insulin resistance, together with impaired mucosal resilience, are associated with shifts in microbial community structure and BA-transforming functions (e.g., bile salt hydrolase and 7α-dehydroxylation), favoring a more hydrophobic BA pool. These changes may disrupt BA receptor signaling, including FXR–FGF15/19 and TGR5-related pathways, thereby amplifying metabolic inflammation, promoting lithogenic bile formation, and impairing gallbladder motility. In parallel, barrier vulnerability may facilitate microbial translocation and LPS-driven immune activation, reinforcing a feed-forward loop that supports the gallstone–inflammation–carcinogenesis trajectory. Translationally, microbiome- and BA-oriented strategies (dietary patterns, bile acid therapeutics, and targeted microbiome modulation) are promising adjuncts, yet precision management should explicitly consider medication- and weight loss–related confounding—particularly with incretin-based therapies—to optimize biliary outcomes across disease stages.